International consensus for neuroblastoma molecular d
International Neuroblastoma Risk Group (INRG) Biolog

British Journal of Cancer

100, 1471-1482

DOI: 10.1038/sj.bjc.6605014

Citation Report

#	Article	IF	Citations
1	Neuroblastoma. Current Problems in Cancer, 2009, 33, 333-360.	1.0	35
2	Neuroblastoma: Biology and staging. Current Oncology Reports, 2009, 11, 431-438.	1.8	88
3	More and better cure for an orphan: priorities for future paediatric cancer research in Europe â€“ Meeting report of the EC-funded science-communication project DIRECT â€œOvercoming Cancer with Researchâ€• Memo - Magazine of European Medical Oncology, 2009, 2, 246-254.	0.3	0
4	Free DNA in the blood serum can unmask MYCN amplified tumors. Pediatric Blood and Cancer, 2009, 53, 306-307.	0.8	1
5	Neuroblastoma: contemporary management. Archives of Disease in Childhood: Education and Practice Edition, 2009, 94, 177-185.	0.3	26
6	The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Medicine, 2009, 1, 74.	3.6	34
7	Targeting PI3K in neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1881-1890.	1.2	19
8	Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma. BMC Genomics, 2010, 11, 298.	1.2	29
9	Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. British Journal of Cancer, 2010, 102, 1319-1326.	2.9	189
10	Gain of MYCN Region in a Wilms Tumor-derived Xenotransplanted Cell Line. Diagnostic Molecular Pathology, 2010, 19, 33-39.	2.1	9
11	A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molecular Cancer, 2010, 9, 185.	7.9	85
12	Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Molecular Cancer, 2010, 9, 277.	7.9	57
13	Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study. Radiotherapy and Oncology, 2010, 97, 593-595.	0.3	11
14	2p24 Gain Region Harboring MYCN Gene Compared with MYCN Amplified and Nonamplified Neuroblastoma. American Journal of Pathology, 2010, 176, 2616-2625.	1.9	22
15	Neuroblastomaâ€”A Model Disease for Childhood Cancer. Journal of the Formosan Medical Association, 2010, 109, 555-557.	0.8	3
16	Fluorescence In Situ Hybridization. Clinics in Laboratory Medicine, 2011, 31, 525-542.	0.7	33
18	Guidelines for Molecular Analysis in Archive Tissues. , 2011, , .		16
19	Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genetics, 2011, 204, 113-121.	0.2	57

#	Article	IF	Citations
20	Activation of the phosphatidylinositol 3â€²-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Human Pathology, 2011, 42, 1727-1739.	1.1	20
21	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq1 1 0.784314 rgBT /Overlock	2.9	82
22	Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci. PLoS Genetics, 2011, 7, e1002026.	1.5	141
23	Prognostic value of partial genetic instability in neuroblastoma with â‰¥50% neuroblastic cell content. Histopathology, 2011, 59, 22-30.	1.6	7
24	Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. Seminars in Cancer Biology, 2011, 21, 217-228.	4.3	70
25	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2011, 29, 3286-3292.	0.8	248
26	Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Review of Neurotherapeutics, 2011, 11, 1411-1423.	1.4	11
27	Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. Journal of Neuro-Oncology, 2011, 102, 25-33.	1.4	20
28	A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell International, 2011, 11, 9.	1.8	27
29	Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975â€“2006. Pediatric Blood and Cancer, 2011, 56, 50-57.	0.8	64
30	Diagnostic and prognostic information obtained on fineâ€needle aspirates of primary neuroblastic tumors. Cancer Cytopathology, 2011, 119, 411-423.	1.4	23
31	Genetic stratification of neuroblastoma for treatment tailoring. Future Oncology, 2011, 7, 1087-1099.	1.1	8
32	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age. Journal of Clinical Oncology, 2011, 29, 4358-4364.	0.8	69
33	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	3.2	39
34	Cooperative Cross-Talk between Neuroblastoma Subtypes Confers Resistance to Anaplastic Lymphoma Kinase Inhibition. Genes and Cancer, 2011, 2, 538-549.	0.6	11
35	How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma. British Journal of Cancer, 2011, 105, 89-92.	2.9	5
37	ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Modern Pathology, 2012, 25, 1516-1525.	2.9	118
39	Letter to the Editor. Journal of Pediatric Surgery, 2012, 47, 2162-2163.	0.8	2

#	Article	IF	Citations
40	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	3.2	59
41	Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma. Clinical Cancer Research, 2012, 18, 5690-5700.	3.2	23
42	Neuroblastoma: Issues in Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S92-S100.	2.0	20
43	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. European Journal of Cancer, 2012, 48, 1185-1191.	1.3	14
44	Neuroblastoma: The impact of biology and cooperation leading to personalized treatments. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 85-115.	2.7	35
45	Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer, 2012, 107, 1418-1422.	2.9	151
46	Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. Cancer Genetics, 2012, 205, 657-664.	0.2	6
47	New prognostic markers in neuroblastoma. Expert Opinion on Medical Diagnostics, 2012, 6, 555-567.	1.6	7
48	A review and update on neuroblastoma. Paediatrics and Child Health (United Kingdom), 2012, 22, 103-107.	0.2	15
49	Acetaminophen Induces Human Neuroblastoma Cell Death through NFKB Activation. PLoS ONE, 2012, 7, e50160.	1.1	36
50	Congenital Malignant Disorders. , 2012, , 1143-1163.		3
51	Genetic Factors Influencing the Risk and Clinical Outcome of Neuroblastoma. , 0, , .		0
52	Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene, 2012, 31, 4828-4834.	2.6	39
53	PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. International Journal of Cancer, 2012, 131, 1556-1568.	2.3	19
54	Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in highâ€risk neuroblastoma. Genes Chromosomes and Cancer, 2012, 51, 545-556.	1.5	16
55	Isolation of disseminated neuroblastoma cells from bone marrow aspirates for pretreatment risk assessment by array comparative genomic hybridization. International Journal of Cancer, 2012, 130, 1098-1108.	2.3	7
56	Peripheral neuroblastic tumors with genotypeâ€“phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood and Cancer, 2013, 60, 363-370.	0.8	25
58	Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 2013, 10, 472-484.	12.5	1,482

#	Article	IF	Citations
59	Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma. Pediatric Surgery International, 2013, 29, 1139-1145.	0.6	27
60	Pathologie der Kindertumoren. , 2013, , 727-802.		0
61	Molecular techniques in anatomic pathology: An overview. Seminars in Diagnostic Pathology, 2013, 30, 263-283.	1.0	5
62	MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genetics, 2013, 206, 124-129.	0.2	13
63	NeuPAT: An intranet database supporting translational research in neuroblastic tumors. Computers in Biology and Medicine, 2013, 43, 219-228.	3.9	4
65	Comprehensive cytogenomic profile of the in vitro neuronal model SH-SY5Y. Neurogenetics, 2013, 14, 63-70.	0.7	47
66	Future of Clinical Genomics in Pediatric Oncology. Journal of Clinical Oncology, 2013, 31, 1893-1903.	0.8	40
67	Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults. Case Reports in Oncological Medicine, 2013, 2013, 1-5.	0.2	4
68	A method for finding consensus breakpoints in the cancer genome from copy number data. Bioinformatics, 2013, 29, 1793-1800.	1.8	8
69	Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers. Oncology Reports, 2013, 29, 2415-2421.	1.2	9
70	Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion. PLoS ONE, 2013, 8, e53740.	1.1	33
71	Molecular oncology of neuroblastoma. , 0, , 669-678.		0
72	A Novel Diagnostic Tool for Therapy Stratification of Neuroblastoma: Preoperative Analysis of Tumor Biology Using Circulating Tumor-Released DNA in Serum. , 2013, , .		0
73	Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN. PLoS ONE, 2014, 9, e101990.	1.1	17
74	Milestones in the Curability of Pediatric Cancers. Journal of Clinical Oncology, 2014, 32, 2391-2397.	0.8	79
75	Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatric Research, 2014, 75, 302-314.	1.1	17
76	Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. Frontiers in Oncology, 2014, 4, 202.	1.3	44
78	Chromosome 17/17q gain and unaltered profiles in high resolution arrayâ€CGH are prognostically informative in neuroblastoma. Genes Chromosomes and Cancer, 2014, 53, 639-649.	1.5	34

#	Article	IF	Citations
79	An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma Chemoresistance. Genetics Research International, 2014, 2014, 1-13.	2.0	7
80	Pediatric Hematology-Oncology in Countries with Limited Resources. , 2014, , .		7
81	The molecular genetic profile of neuroblastoma. Diagnostic Histopathology, 2014, 20, 76-83.	0.2	3
82	Molecular Testing in Cancer. , 2014, , .		2
83	Proteomics of dedifferentiation of SK-N-BE2 neuroblastoma cells. Biochemical and Biophysical Research Communications, 2014, 454, 202-209.	1.0	6
84	Early Targets of miR-34a in Neuroblastoma. Molecular and Cellular Proteomics, 2014, 13, 2114-2131.	2.5	29
85	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	2.3	25
86	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2014, 32, 3169-3176.	0.8	154
87	Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: A European HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2014, 32, 1074-1083.	0.8	97
88	Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. Journal of Neuro-Oncology, 2014, 119, 17-26.	1.4	29
89	Open versus needle biopsy in diagnosing neuroblastoma. Journal of Pediatric Surgery, 2014, 49, 1505-1507.	0.8	29
91	Striking dichotomy in outcome of MYCNâ€amplified neuroblastoma in the contemporary era. Cancer, 2014, 120, 2050-2059.	2.0	36
92	Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. Cancer Science, 2015, 106, 766-771.	1.7	18
93	Translational compensation of genomic instability in neuroblastoma. Scientific Reports, 2015, 5, 14364.	1.6	11
94	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1368-1373.	0.8	22
95	Phenotype and Immunophenotype of the Most Common Pediatric Tumors. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 313-326.	0.6	13
96	Antagonizing Bcl-2 Family Members Sensitizes Neuroblastoma and Ewingâ€™s Sarcoma to an Inhibitor of Glutamine Metabolism. PLoS ONE, 2015, 10, e0116998.	1.1	12
97	SIOPâ€PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in lowâ€and middleâ€income settings. Pediatric Blood and Cancer, 2015, 62, 1305-1316.	0.8	73

#	Article	IF	Citations
99	Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses. Molecular Oncology, 2015, 9, 545-554.	2.1	18
100	Endoglin (CD 105) as a potential prognostic factor in neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 770-775.	0.8	7
101	Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. Nature Communications, 2015, 6, 6125.	5.8	58
102	MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 222-230.	3.3	16
103	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer, 2015, 112, 290-295.	2.9	39
104	The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins. Modern Pathology, 2015, 28, 166-176.	2.9	5
105	Identifying Rare Events in Rare Diseases. Clinical Cancer Research, 2015, 21, 1782-1785.	3.2	9
106	Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer, 2015, 15, 514.	1.1	46
107	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 2015, 33, 3008-3017.	0.8	637
108	Solid Tumors of Childhood Display Specific Serum microRNA Profiles. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 350-360.	1.1	74
109	Neuroblastoma. Pediatric Clinics of North America, 2015, 62, 225-256.	0.9	328
110	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. Journal of Molecular Diagnostics, 2015, 17, 43-52.	1.2	19
111	Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction. Journal of Korean Medical Science, 2016, 31, 1392.	1.1	9
113	Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors. PLoS ONE, 2016, 11, e0161369.	1.1	5
114	Spontaneous Maturation of Neuroblastoma to Ganglioneuroma: Two Case Studies. Fetal and Pediatric Pathology, 2016, 35, 410-415.	0.4	4
115	N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics. Cell Death Discovery, 2016, 2, 16082.	2.0	35
116	Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood. Expert Review of Neurotherapeutics, 2016, 16, 465-467.	1.4	1
117	Diagnostic implications of intrapatient genetic tumor heterogeneity. Molecular and Cellular Oncology, 2016, 3, e1079671.	0.3	6

#	Article	IF	Citations
118	Neuroblastoma (Peripheral neuroblastic tumours). Critical Reviews in Oncology/Hematology, 2016, 107, 163-181.	2.0	101
119	The genetic tumor background is an important determinant for heterogeneous MYCNâ€amplified neuroblastoma. International Journal of Cancer, 2016, 139, 153-163.	2.3	32
120	Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. , 2016, , .		6
121	Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. British Journal of Cancer, 2016, 115, 480-489.	2.9	46
122	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clinical Cancer Research, 2016, 22, 5564-5573.	3.2	108
123	Neuroblastoma. Nature Reviews Disease Primers, 2016, 2, 16078.	18.1	907
124	Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer, 2016, 122, 935-945.	2.0	58
125	The SIOPE strategic plan: A European cancer plan for children and adolescents. Journal of Cancer Policy, 2016, 8, 17-32.	0.6	57
126	Guidelines for cytogenetic investigations in tumours. European Journal of Human Genetics, 2016, 24, 6-13.	1.4	28
128	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Childrenâ€™s Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 474-481.	3.3	19
129	Revisiting tumour aneuploidy â€" the place of ploidy assessment in the molecular era. Nature Reviews Clinical Oncology, 2016, 13, 291-304.	12.5	119
130	Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene, 2016, 35, 1423-1432.	2.6	27
131	Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. Journal of Hematology and Oncology, 2017, 10, 108.	6.9	35
132	Management of Neuroblastoma: ICMR Consensus Document. Indian Journal of Pediatrics, 2017, 84, 446-455.	0.3	29
133	MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma. Cancer Cell International, 2017, 17, 43.	1.8	27
134	Ultrasound-guided core needle biopsy in the diagnosis of neuroblastic tumors in children: a retrospective study on 83 cases. Pediatric Surgery International, 2017, 33, 347-353.	0.6	19
135	Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation. Scientific Reports, 2017, 7, 13612.	1.6	24
136	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	2.0	97

#	Article	IF	Citations
138	Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Reports, 2017, 19, 2544-2556.	2.9	75
139	Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. Pediatric Hematology and Oncology, 2017, 34, 165-185.	0.3	76
140	Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma. Oncotarget, 2017, 8, 37730-37739.	0.8	52
141	Quercetin-mediated synthesis of graphene oxide–silver nanoparticle nanocomposites: a suitable alternative nanotherapy for neuroblastoma. International Journal of Nanomedicine, 2017, Volume 12, 5819-5839.	3.3	54
142	Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS ONE, 2017, 12, e0185190.	1.1	40
143	CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric Neuroblastoma. Journal of Stem Cell Research & Therapy, 2017, 07, .	0.3	0
144	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	0.8	219
145	Molecular Testing in Pediatric Cancers. , 2017, , 401-410.		0
146	Cross-Cohort Analysis Identifies a TEAD4â€“MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discovery, 2018, 8, 582-599.	7.7	119
147	Investigation of major genetic alterations in neuroblastoma. Molecular Biology Reports, 2018, 45, 287-295.	1.0	14
149	Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatric and Developmental Pathology, 2018, 21, 461-466.	0.5	11
150	CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. Journal of International Medical Research, 2018, 46, 1209-1220.	0.4	13
151	Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell and Tissue Research, 2018, 372, 195-209.	1.5	184
152	Zebrafish as a model to study neuroblastoma development. Cell and Tissue Research, 2018, 372, 223-232.	1.5	9
153	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2018, 40, 93-98.	0.3	11
154	The role of N-Myc gene amplification in neuroblastoma childhood tumour â€“ single-centre experience. Wspolczesna Onkologia, 2018, 22, 223-228.	0.7	9
155	Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma. PLoS ONE, 2018, 13, e0208924.	1.1	16
156	Both serum and tissue Galectinâ€1 levels are associated with adverse clinical features in neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27229.	0.8	10

#	Article	IF	Citations
157	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. British Journal of Cancer, 2018, 118, 1502-1512.	2.9	28
158	Comparison of the human tumor metastasis gene expression level in neuroblastoma patients with MYCN amplification and 2p gain: Pilot study. Pediatric Hematology Oncology Journal, 2018, 3, 48-50.	0.1	1
159	Neuroblastoma and Neuroblastic Tumors. Molecular Pathology Library, 2018, , 151-168.	0.1	0
160	MiRNA Influences in Neuroblast Modulation: An Introspective Analysis. Genes, 2018, 9, 26.	1.0	10
161	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	0.8	53
162	Congenital Malignant Disorders. , 2018, , 1219-1237.e3.		2
163	Paediatric Tumours of Neuroendocrine/Peripheral Neuroectodermal Origin. , 2018, , 235-251.		0
164	Survival Differences Between Males and Females Diagnosed With Childhood Cancer. JNCI Cancer Spectrum, 2019, 3, pkz032.	1.4	26
165	High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. BMC Cancer, 2019, 19, 1.	1.1	420
166	Diagnostic ultrasound-guided cutting needle biopsies in neuroblastoma: A safe and efficient procedure. Journal of Pediatric Surgery, 2019, 54, 1253-1256.	0.8	8
167	131I-MIBG Therapy of Malignant Neuroblastoma and Pheochromocytoma. , 2019, , 65-83.		2
168	Nuclear Medicine Therapy. , 2019, , .		5
169	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2019, 66, e27819.	0.8	20
170	A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients. Japanese Journal of Clinical Oncology, 2019, 49, 743-748.	0.6	13
171	Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biology, 2019, 9, 190056.	1.5	22
172	Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma. , 2019, , 23-41.		0
173	The Evolution of Risk Classification for Neuroblastoma. Children, 2019, 6, 27.	0.6	65
174	Neuroblastomaâ€"A Neural Crest Derived Embryonal Malignancy. Frontiers in Molecular Neuroscience, 2019, 12, 9.	1.4	166

#	Article	IF	Citations
175	Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain. Frontiers in Oncology, 2019, 9, 1018.	1.3	12
176	Multifunctional nanocarrier as a potential micro-RNA delivery vehicle for neuroblastoma treatment. Journal of the Taiwan Institute of Chemical Engineers, 2019, 96, 526-537.	2.7	16
177	FISH Testing of Cytology Specimens: Pre-analytic, Analytic, and Post-analytic Considerations. , 2019, , 121-159.		0
179	Adultâ€onset neuroblastoma: Report of seven cases with molecular genetic characterization. Genes Chromosomes and Cancer, 2020, 59, 240-248.	1.5	11
180	Bone and bone marrow involvement in neuroblastoma. Medicine (United States), 2020, 99, e22505.	0.4	2
181	In situ hybridisation in tissue sections. Diagnostic Histopathology, 2020, 26, 521-528.	0.2	1
182	New Prognostic Indicators in Pediatric Adrenal Tumors. Surgical Pathology Clinics, 2020, 13, 625-641.	0.7	6
183	Implementation of the plasma MYCN / NAGK ratio to detect MYCN amplification in patients with neuroblastoma. Molecular Oncology, 2020, 14, 2884-2893.	2.1	6
184	Stem cells, evolutionary aspects and pathology of the adrenal medulla: A new developmental paradigm. Molecular and Cellular Endocrinology, 2020, 518, 110998.	1.6	19
185	Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers, 2020, 12, 2057.	1.7	48
186	Inhibition of mitotic kinase Mps1 promotes cell death in neuroblastoma. Scientific Reports, 2020, 10, 11997.	1.6	17
187	MYC in Brain Development and Cancer. International Journal of Molecular Sciences, 2020, 21, 7742.	1.8	20
188	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	0.8	9
189	An overview of neuroblastoma cell lineage phenotypes andin vitromodels. Experimental Biology and Medicine, 2020, 245, 1637-1647.	1.1	28
190	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. Journal of Molecular Diagnostics, 2020, 22, 1309-1323.	1.2	11
191	Peripheral neuroblastic tumors of the adrenal gland: clinicopathologic features and important molecular alterations. Diagnostic Histopathology, 2020, 26, 200-206.	0.2	1
192	Association of heterogeneous MYCN amplification with clinical features, biological characteristicsÂand outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	1.3	13
193	Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology, 2020, 38, 1836-1848.	0.8	74

#	Article	IF	Citations
194	Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2020, 38, 2902-2915.	0.8	60
195	Genitourinary Pathology (Including Adrenal Gland). , 2020, , 1523-1726.		0
196	Genomic subtyping of liver cancers with prognostic application. BMC Cancer, 2020, 20, 84.	1.1	6
197	MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex. Oncogene, 2020, 39, 4212-4226.	2.6	9
198	Combined Replenishment of miRâ€34a and letâ€7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. Small, 2020, 16, e1906426.	5.2	27
199	Epigenomic profiling of neuroblastoma cell lines. Scientific Data, 2020, 7, 116.	2.4	32
200	Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy. Journal of Radiotherapy in Practice, 2021, 20, 217-229.	0.2	0
201	Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification. European Radiology, 2021, 31, 3080-3089.	2.3	27
202	Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs. Cell Biology and Toxicology, 2021, 37, 461-478.	2.4	11
203	The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28819.	0.8	2
204	Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Seminars in Cancer Biology, 2021, 69, 100-108.	4.3	42
205	Comprehensive Analysis and Validation Reveal Potential MYCN Regulatory Biomarkers Associated with Prognosis of Neuroblastoma. SSRN Electronic Journal, 0, , .	0.4	0
206	Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake. JCO Precision Oncology, 2021, 5, 275-285.	1.5	3
207	Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry. Pediatric Blood and Cancer, 2021, 68, e28904.	0.8	3
208	BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma. Cancers, 2021, 13, 817.	1.7	13
209	Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94. Cancers, 2021, 13, 572.	1.7	0
210	Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification. Pathology International, 2021, 71, 232-244.	0.6	9
211	Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan. Bone Marrow Transplantation, 2021, 56, 2173-2182.	1.3	3

#	Article	IF	Citations
212	Proteomic investigation of Cbl and Cbl-b in neuroblastoma cell differentiation highlights roles for SHP-2 and CDK16. IScience, 2021, 24, 102321.	1.9	8
213	SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability. Reviews in the Neurosciences, 2022, 33, 1-15.	1.4	35
214	Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study. Pediatric Blood and Cancer, 2021, 68, e29110.	0.8	16
215	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	0.8	30
216	Mediastinal neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Pathology review and diagnostic approach. Seminars in Diagnostic Pathology, 2022, 39, 120-130.	1.0	10
218	Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis. Angiogenesis, 2022, 25, 71-86.	3.7	25
219	Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. , 2021, 9, e002267.		14
220	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	0.8	174
221	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing. Journal of Personalized Medicine, 2021, 11, 691.	1.1	2
222	Nasal metastases from neuroblastoma-a rare entity: Two case reports. World Journal of Clinical Cases, 2021, 9, 6816-6823.	0.3	0
223	Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. Cancers, 2021, 13, 4360.	1.7	1
224	Residual metaâ€iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome. Pediatric Blood and Cancer, 2021, 68, e29289.	0.8	1
225	High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy. Current Cancer Therapy Reviews, 2022, 18, 14-40.	0.2	1
226	Comparison of Next-Generation Sequencing and Fluorescence In Situ Hybridization for Detection of Segmental Chromosomal Aberrations in Neuroblastoma. Diagnostics, 2021, 11, 1702.	1.3	3
227	Pathology of the Orbit: Neoplasms. , 2021, , 1-61.		0
228	The Cytogenetics of Solid Tumors. , 2013, , 371-411.		2
229	Cytogenetics of Solid Tumours. Methods in Molecular Biology, 2011, 730, 173-187.	0.4	3
231	Adrenal gland and other paraganglia. , 2011, , 1057-1100.		3

#	Article	IF	Citations
232	Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis. British Journal of Cancer, 2020, 122, 1077-1084.	2.9	13
234	Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification. Oncotarget, 2017, 8, 49689-49701.	0.8	5
235	MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget, 2017, 8, 95293-95302.	0.8	10
236	Metronomic topotecan impedes tumor growth ofMYCN-amplified neuroblastoma cellsin vitroandin vivoby therapy induced senescence. Oncotarget, 2016, 7, 3571-3586.	0.8	39
237	Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors. Oncotarget, 2016, 7, 19935-19947.	0.8	22
238	Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data. Oncotarget, 2016, 7, 36293-36310.	0.8	37
239	Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population. Journal of Korean Medical Science, 2020, 35, e82.	1.1	4
240	ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor. Cancer Research and Treatment, 2018, 50, 495-505.	1.3	12
241	YM155 Inhibits Neuroblastoma Cell Migration and Survival <i>in Vitro</i> and Tumor Growth and Metastatic Burden in a Pre-Clinical Model. Journal of Cancer Therapy, 2014, 05, 1289-1302.	0.1	2
242	Neuroblastomas in Eastern China: a retrospective series study of 275 cases in a regional center. PeerJ, 2018, 6, e5665.	0.9	3
243	Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma. Cancers, 2021, 13, 5173.	1.7	8
244	Neuroblastomaâ€"Telomere maintenance, deregulated signaling transduction and beyond. International Journal of Cancer, 2022, 150, 903-915.	2.3	11
245	Genetic Prognostic Markers in Neuroblastoma. North American Journal of Medicine & Science, 2010, 3, 123.	3.8	0
247	A Comprehensive Tissue Microarray-Based FISH Screen of ALK Gene in Neuroblastomas. Pediatric Cancer, 2012, , 65-75.	0.0	0
248	MYCN Nonamplified Neuroblastoma: Detection of Tumor-Derived Cell-Free DNA in Serum for Predicting Prognosis of Neuroblastoma. Pediatric Cancer, 2013, , 11-17.	0.0	0
249	Molecular pathology. , 2013, , 455-491.		0
252	Molecular Testing in Paediatric Tumours. , 2014, , 375-403.		0
253	Conventional and Molecular Cytogenetics in Cancer. , 2014, , 15-25.		0

#	Article	IF	Citations
254	Milestones in the curability of pediatric cancers. Russian Journal of Pediatric Hematology and Oncology, 2015, , 32-40.	0.1	0
255	Adrenal Neuroendocrine Tumors: Pheochromocytoma and Neuroblastic Tumors. , 2016, , 323-357.		0
256	Neuroblastoma and Ganglioneuroblastoma. , 2016, , 808-817.		0
258	Neuroblastoma, Cytological Findings. Encyclopedia of Pathology, 2017, , 316-323.	0.0	0
260	Neuroblastic Tumors of Adrenal Gland. , 2018, , 492-503.		0
261	Neuroblastoma and Ganglioneuroblastoma. , 2018, , 492-501.		0
262	Nuclear Medicine Procedures in Neuroblastoma. , 2020, , 139-162.		0
263	High-Risk Neuroblastoma and Current Protocols. , 2020, , 213-235.		1
264	Biopsy of Neuroblastoma. , 2020, , 295-311.		0
265	Prognostic Factors and Risk Stratification. , 2020, , 271-292.		0
266	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	2.1	10
267	Small-molecule Inhibitors of Mycâ€“Max Interaction and DNA Binding. RSC Drug Discovery Series, 2020, , 302-338.	0.2	0
268	A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma. Cancers, 2021, 13, 5528.	1.7	16
269	Pathology of Peripheral Neuroblastic Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 73-86.	0.0	2
270	Typical numerical alterations in genome identified by array CGH analysis in neuroblastoma tumors. AIMS Molecular Science, 2021, 8, 248-256.	0.3	0
272	Liquid biopsies in pediatric oncology: opportunities and obstacles. Current Opinion in Pediatrics, 2022, 34, 39-47.	1.0	5
273	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Nature Communications, 2021, 12, 6804.	5.8	39
274	ecDNA hubs drive cooperative intermolecular oncogene expression. Nature, 2021, 600, 731-736.	13.7	123

#	Article	IF	Citations
275	Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. JCO Precision Oncology, 2022, 6, e2000447.	1.5	4
276	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resourceâ€limited countries. Pediatric Blood and Cancer, 2022, 69, e29568.	0.8	6
278	Molecular Markers of Pediatric Solid Tumorsâ€"Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions. Cells, 2022, 11, 1238.	1.8	7
279	Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Childrenâ€™s Cancer Group Neuroblastoma Committee (JCCG-JNBSG). Biomolecules, 2022, 12, 18.	1.8	7
280	Thoracic Neuroblastoma: A Novel Surgical Model for the Study of Extra-adrenal Neuroblastoma. In Vivo, 2022, 36, 49-56.	0.6	2
281	Whole-tumour apparent diffusion coefficient (ADC) histogram analysis to identify MYCN-amplification in neuroblastomas: preliminary results. European Radiology, 2022, 32, 8453-8462.	2.3	10
282	CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma. Child's Nervous System, 2022, 38, 1487-1495.	0.6	13
283	Pathology of the Orbit: Neoplasms. , 2022, , 6427-6487.		0
284	Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma. Cancers, 2022, 14, 2627.	1.7	10
285	Tumors of the nervous system. , 2023, , 203-228.		1
286	DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma. JCI Insight, 2022, 7, .	2.3	11
287	An 18F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System. European Journal of Radiology, 2022, 154, 110444.	1.2	10
288	A Random Forest-based Classifier for MYCN Status Prediction in Neuroblastoma using CT Images. , 2022, , .		1
289	The evolutionary dynamics of extrachromosomal DNA in human cancers. Nature Genetics, 2022, 54, 1527-1533.	9.4	44
290	MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. Cancers, 2022, 14, 4421.	1.7	12
292	LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2. Cell Death and Disease, 2022, 13, .	2.7	4
293	Learning-Based Detection ofÂMYCN Amplification inÂClinical Neuroblastoma Patients: A Pilot Study. Lecture Notes in Computer Science, 2022, , 89-97.	1.0	0
294	Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis. Journal of Biomolecular Structure and Dynamics, 2023, 41, 8902-8917.	2.0	1

#	Article	IF	Citations
295	In Vitro Transfection of Up-Regulated Genes Identified in Favorable-Outcome Neuroblastoma into Cell Lines. Cells, 2022, 11, 3171.	1.8	0
296	A Novel Online Nomogram Established with Five Features before Surgical Resection for Predicating Prognosis of Neuroblastoma Children: A Population-Based Study. Technology in Cancer Research and Treatment, 2023, 22, 153303382211451.	0.8	0
298	Comparative genetic profiling of neuroblastoma at the onset vs recurrence or progression of the tumor and determination of the prognostic role of genetic alterations. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 18-30.	0.1	0
299	P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma. Molecular and Cellular Proteomics, 2023, 22, 100504.	2.5	3
300	The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN. Cells, 2023, 12, 544.	1.8	0
301	Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma. Pediatric and Developmental Pathology, 2023, 26, 124-132.	0.5	2
302	Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective study. European Journal of Pediatrics, 2023, 182, 2189-2196.	1.3	2
303	Mitochondria-associated gene expression perturbation predicts clinical outcomes and shows potential for targeted therapy in neuroblastoma. Frontiers in Pediatrics, 0, 11, .	0.9	0
304	Role of surgery in neuroblastoma. Pediatric Surgery International, 2023, 39, .	0.6	1
306	Congenital Malignant Disorders. , 2024, , 1067-1085.e5.		0
319	Molecular testing in pediatric cancers. , 2024, , 475-484.		0
321	A narrative review of radiomics and deep learning advances in neuroblastoma: updates and challenges. Pediatric Radiology, 2023, 53, 2742-2755.	1.1	0